Subtopic Deep Dive

← Drug-Induced Hepatotoxicity and Protection

Biomarkers of Drug-Induced Liver Injury
Research Guide

What is Biomarkers of Drug-Induced Liver Injury?

Biomarkers of drug-induced liver injury (DILI) are measurable indicators such as microRNA-122, keratin-18 fragments, and glutamate dehydrogenase used for early detection and severity prediction of hepatotoxicity compared to traditional ALT levels.

Research develops and validates novel biomarkers outperforming ALT in sensitivity and specificity for DILI. Studies focus on microRNA-122 and keratin-18 in clinical trials and patient monitoring. Over 10 key papers since 2011 address biomarker performance in DILI contexts.

Curated Papers

Key Challenges

Why It Matters

Superior DILI biomarkers enable earlier detection during drug development, reducing trial failures and patient risks (Andrade et al., 2019; Kullak-Ublick et al., 2017). They improve causality assessment with tools like RUCAM, aiding regulatory decisions (Danan and Teschke, 2015). In acetaminophen overdose cases, biomarkers predict severity better than ALT, enhancing management (Yoon et al., 2016).

Key Research Challenges

Biomarker Specificity vs ALT

Novel biomarkers like microRNA-122 show higher sensitivity but struggle with specificity in mixed liver injuries. Comparative studies reveal overlaps with chronic conditions (Kullak-Ublick et al., 2017). Validation across diverse populations remains limited.

Causality Assessment Integration

Linking biomarkers to drug-specific injury requires integration with RUCAM scoring amid confounding factors. Idiosyncratic DILI complicates attribution (Danan and Teschke, 2015; Andrade et al., 2019). Standardized protocols are lacking.

Early Detection Validation

Preclinical models like hepatocyte spheroids validate biomarkers but translation to humans varies. Clinical trial data show inconsistent prediction of severe outcomes (Bell et al., 2016). Longitudinal studies are needed.

Essential Papers

Global burden of liver disease: 2023 update

Harshad Devarbhavi, Sumeet K. Asrani, Juan Pablo Arab et al. · 2023 · Journal of Hepatology · 1.7K citations

Liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related deaths occur in me...

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

Shiv Kumar Sarin, Chandan Kumar Kedarisetty, Zaigham Abbas et al. · 2014 · Hepatology International · 1.5K citations

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Shiv Kumar Sarin, Ashok Choudhury, Manoj Kumar et al. · 2019 · Hepatology International · 842 citations

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. Wi...

Drug-induced liver injury

Raúl J. Andrade, Naga Chalasani, Einar S. Björnsson et al. · 2019 · Nature Reviews Disease Primers · 729 citations

Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update

Eric Yoon, Arooj Babar, Moaz M. Choudhary et al. · 2016 · Journal of Clinical and Translational Hepatology · 728 citations

Hepatic injury and subsequent hepatic failure due to both intentional and non-intentional overdose of acetaminophen (APAP) has affected patients for decades, and involves the cornerstone metabolic ...

RUCAM in Drug and Herb Induced Liver Injury: The Update

Gaby Danan, Rolf Teschke · 2015 · International Journal of Molecular Sciences · 716 citations

RUCAM (Roussel Uclaf Causality Assessment Method) or its previous synonym CIOMS (Council for International Organizations of Medical Sciences) is a well established tool in common use to quantitativ...

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

Catherine C. Bell, Delilah Hendriks, Sabrina Moro et al. · 2016 · Scientific Reports · 682 citations

Reading Guide

Foundational Papers

Start with Sarin et al. (2014, 1477 citations) for ACLF context in DILI; Ramappa and Aithal (2012, 491 citations) for anti-TB hepatotoxicity mechanisms; Chen et al. (2011, 392 citations) for FDA labeling insights.

Recent Advances

Study Andrade et al. (2019, 729 citations) for DILI overview; Kullak-Ublick et al. (2017, 469 citations) for risk assessment advances; Devarbhavi et al. (2023, 1660 citations) for global burden updates.

Core Methods

Core methods: RUCAM causality scoring (Danan and Teschke, 2015); hepatocyte spheroids for validation (Bell et al., 2016); ALT biomarker comparisons in trials (Yoon et al., 2016).

How PapersFlow Helps You Research Biomarkers of Drug-Induced Liver Injury

Discover & Search

Research Agent uses searchPapers and exaSearch to find DILI biomarker papers like 'Drug-induced liver injury' by Andrade et al. (2019), then citationGraph reveals connections to RUCAM updates by Danan and Teschke (2015), and findSimilarPapers uncovers validation studies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract biomarker data from Yoon et al. (2016) on acetaminophen, verifies claims with CoVe against ALT comparisons, and runs PythonAnalysis for statistical meta-analysis of sensitivity metrics using pandas, with GRADE grading for evidence quality.

Synthesize & Write

Synthesis Agent detects gaps in biomarker specificity via contradiction flagging across papers, while Writing Agent uses latexEditText, latexSyncCitations for Andrade et al. (2019), and latexCompile to generate review sections with exportMermaid for biomarker comparison diagrams.

Use Cases

"Run stats on microRNA-122 sensitivity vs ALT in DILI trials from 2015-2023"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of extracted data) → matplotlib plots of AUC comparisons.

"Draft LaTeX review comparing keratin-18 biomarkers to RUCAM in hepatotoxicity papers"

Research Agent → citationGraph → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with citations.

"Find GitHub repos with DILI biomarker simulation code from recent papers"

Research Agent → paperExtractUrls on Bell et al. (2016) → paperFindGithubRepo → githubRepoInspect → code snippets for hepatocyte spheroid models.

Automated Workflows

Deep Research workflow scans 50+ DILI papers via searchPapers, structures biomarker comparisons in a report with GRADE scores. DeepScan applies 7-step CoVe to validate microRNA-122 claims against Andrade et al. (2019). Theorizer generates hypotheses on biomarker panels from citationGraph of Sarin et al. (2014) and updates.

Try Doxa for Biomarkers of Drug-Induced Liver Injury Research

Frequently Asked Questions

What defines biomarkers of DILI?

Biomarkers are indicators like microRNA-122 and keratin-18 for early DILI detection outperforming ALT, validated in clinical studies (Kullak-Ublick et al., 2017).

What methods assess DILI biomarkers?

Methods include RUCAM for causality and comparative AUC analysis against ALT in trials (Danan and Teschke, 2015; Andrade et al., 2019).

What are key papers on DILI biomarkers?

Andrade et al. (2019, 729 citations) reviews DILI; Kullak-Ublick et al. (2017, 469 citations) advances diagnosis; Yoon et al. (2016, 728 citations) covers acetaminophen models.

What open problems exist in DILI biomarkers?

Challenges include specificity in chronic liver disease, clinical translation from spheroid models, and standardized panels (Bell et al., 2016; Kullak-Ublick et al., 2017).